肺原发性淋巴上皮瘤样癌中缺乏外显子 19 和 21 的表皮生长因子受体基因突变。
Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung.
机构信息
State Key Laboratory of Oncology in South China Guangzhou, China; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center Guangzhou, China.
State Key Laboratory of Oncology in South China Guangzhou, China; Department of Pathology, Sun Yat-sen University Cancer Center Guangzhou, China.
出版信息
Thorac Cancer. 2014 Jan;5(1):63-7. doi: 10.1111/1759-7714.12060. Epub 2014 Jan 2.
BACKGROUND
Primary lymphoepithelioma-like carcinoma (LELC) of the lung is uncommon in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) targeted therapy has been applied in advanced common NSCLC. Whether EGFR-targeted therapy is also suitable for LELC of the lung remains unclear. As we know, EGFR gene mutation is a predictive factor. Therefore, EGFR gene mutations in exons 19 and 21 in Chinese patients with LELC of the lung were investigated.
METHODS
Clinicopathological information was obtained by a retrospective review of the medical history recorded in the patients' charts. EGFR gene mutations in exons 19 and 21 were analyzed in 32 samples of LELC of the lung by TaqMan real-time polymerase chain reaction (RT-PCR).
RESULTS
Eleven (34.4%) of the patients were male and 21 (65.6%) patients female. The mean age at diagnosis was 50.9 years (range, 25-71 years). Seven (21.9%) of the patients were smokers. In situ hybridization for Epstein-Barr virus-encoded small RNAs (EBERs) showed positive signals in all 32 patients. None of the tumors had mutations in exons 19 and 21. EGFR-targeted therapy was used in three patients with advanced disease and one patient with distant recurrence. However, no obvious therapeutic effect was found.
CONCLUSION
These data showed that LELC of the lung, a special histological type of lung cancer, lacked EGFR gene mutations in exons 19 and 21, which suggested that there was no opportunity for EGFR-targeted therapy for patients with LELC of the lung.
背景
肺原发性淋巴上皮瘤样癌（LELC）在非小细胞肺癌（NSCLC）中较为少见。表皮生长因子受体（EGFR）靶向治疗已应用于晚期常见 NSCLC。EGFR 靶向治疗是否也适用于肺 LELC 尚不清楚。据我们所知，EGFR 基因突变是一个预测因素。因此，我们研究了中国肺 LELC 患者 EGFR 基因外显子 19 和 21 的突变情况。
方法
通过回顾患者病历中记录的病史，获得临床病理信息。通过 TaqMan 实时聚合酶链反应（RT-PCR）分析 32 例肺 LELC 样本中 EGFR 基因外显子 19 和 21 的突变情况。
结果
11 例（34.4%）患者为男性，21 例（65.6%）患者为女性。诊断时的平均年龄为 50.9 岁（范围，25-71 岁）。7 例（21.9%）患者为吸烟者。所有 32 例患者的原位杂交均显示 Epstein-Barr 病毒编码的小 RNA（EBERs）阳性信号。没有一个肿瘤在 19 和 21 外显子上有突变。有 3 例晚期疾病患者和 1 例远处复发患者接受了 EGFR 靶向治疗。然而，未发现明显的治疗效果。
结论
这些数据表明，肺 LELC 是一种特殊的肺癌组织学类型，缺乏外显子 19 和 21 的 EGFR 基因突变，这表明肺 LELC 患者没有接受 EGFR 靶向治疗的机会。
Zotero 插件